EAST HANOVER, NJThe driving force behind Novartis
Oncologys new oncology/hematology website is
practicalityproviding practical information in an easily
accessible manner. The new site, for oncologists,
hematologists,nurses, patients, and consumers, is located at www.novartisoncology.com.
The site includes information on Novartis Living With Cancer
Initiative, a multifaceted program for patients that provides
information on clinical trials and cancer organizations.
Another feature of the site is an explanation of Novartis
three-tiered approach to conducting research: at the cellular level
(addressing multidrug resistance and investigating antiproliferative
agents to inhibit cancer cell growth); the host/tumor level
(disrupting host/tumor interaction through the inhibition of
angiogenesis and tumor metastasis); and the patient support level
(overcoming the sequelae of cancer and the side ffects of its treatment).
The website also provides a brief overview of Novartis Oncology
products, but more extensive information is available through
hotlinks to the companys product-specific websites on Aredia
(pamid-ronate disodium for injection), Femara (letrozole tablets),
and Sandostatin LAR Depot (octreotide acetate for injectable
Aredia is approved for the treatment of osteolytic bone metastases in
patients with multiple myeloma or breast cancer in conjunction with
standard antineoplastic therapy; hypercalcemia of malignancy; and
Pagets disease. The website is located at www.Aredia.net.
The Femara website (located at www.femara.com)
offers extensive information on the role of Femara, an aromatase
inhibitor, in treating advanced breast cancer patients. The agent is
approved for use in advanced breast cancer in postmenopausal women
with disease progression after antiestrogen therapy.
The website includes, for physicians, a treatment algorithm visually
depicting the point at which aromatase inhibitors and specifically
Femara should be considered.
For patients, the Femara site provides educational information on
hormonal agents, including visuals of how Femara deprives cancer
cells of the estrogen that may trigger their growth and
multiplication. Frequently asked questions about Femara are included,
as well as a glossary of terms used in discussions of advanced breast cancer.
Carcinoid Tumor Website
The carcinoid tumor website (www.carcinoidinfo.com)
is designed to provide oncologists and other health care
professionals easy access to information about carcinoid tumors and
carcinoid syndrome. The site houses information on the diseases
pathophysiology, epidemiology, diagnosis, and treatment, as well as a
library of select clinical studies, medical meetings, and related
Extensive information also is available on Novartis Sandostatin
LAR Depot, a once-a-month agent approved for the treatment of
acromegaly and to control the symptoms of vasoactive intestinal
peptide-secreting tumors (VIPomas).